CLYM
Climb Bio, Inc. NASDAQ Listed Aug 10, 2021$11.45
+0.97%
vs $11.34
Mkt Cap $776.4M
52w Low $1.18
93.0% of range
52w High $12.22
50d MA $10.33
200d MA $5.51
P/E (TTM)
-13.0x
EV/EBITDA
—
P/B
4.8x
Debt/Equity
0.0x
ROE
-37.3%
P/FCF
-14.2x
RSI (14)
54.00
ATR (14)
$1.04
Beta
-0.20
50d MA
$10.33
200d MA
$5.51
Avg Volume
1.0M
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
PMB #117, 2801 Centerville Road · Wellesley Hills, DE 19808-1609 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.20 | -0.26 | -30.0% | 7.39 | -0.4% | -2.8% | +1.0% | +1.1% | +0.0% | -1.0% | — |
| Nov 6, 2025 | AMC | -0.16 | -0.19 | -18.8% | 1.95 | -3.1% | -6.2% | -1.6% | +5.6% | +1.1% | -2.6% | — |
| Aug 12, 2025 | AMC | -0.19 | -0.13 | +31.6% | 1.61 | +2.5% | +1.2% | +5.5% | +10.5% | +11.1% | -4.3% | — |
| May 14, 2025 | AMC | -0.15 | -0.31 | -106.7% | 1.17 | +0.0% | +2.6% | +7.5% | -1.6% | -2.4% | -2.4% | — |
| Mar 25, 2025 | AMC | -0.15 | -0.13 | +13.3% | 1.30 | +3.1% | +0.0% | -2.3% | +0.8% | -4.7% | -1.6% | — |
| Nov 12, 2024 | AMC | — | -0.13 | — | 3.80 | +6.3% | -7.1% | -9.3% | -5.9% | +1.7% | +6.2% | — |
| Aug 14, 2024 | AMC | — | -1.81 | — | — | — | — | — | — | — | — | — |
| May 15, 2024 | AMC | — | -0.06 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | -0.13 | -0.13 | -2.5% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | -0.14 | -0.15 | -4.7% | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | -0.16 | -0.19 | -21.6% | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | -0.25 | -0.84 | -236.0% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 8 | Guggenheim | Initiates | Buy | $35 | $10.55 | $11.05 | +4.7% | +2.1% | +3.4% | -3.1% | +1.0% | +4.9% |
| May 5 | Chardan Capital Markets | Initiates | Buy | $22 | $9.69 | $9.93 | +2.5% | +18.2% | +6.7% | -2.5% | -4.5% | -2.2% |
| Apr 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.97 | $9.24 | +3.0% | +4.5% | -0.7% | -3.0% | +1.3% | +3.9% |
| Apr 8 | BTIG | Maintains | Buy → Buy | — | $6.87 | $7.10 | +3.3% | +3.3% | +13.4% | +4.5% | +2.6% | +2.5% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.25 | $7.48 | +3.2% | +1.1% | +0.0% | -1.0% | -3.2% | +1.4% |
| Mar 6 | Baird | Maintains | Outperform → Outperform | — | $7.39 | $7.36 | -0.4% | -2.8% | +1.0% | +1.1% | +0.0% | -1.0% |
| Mar 6 | Wedbush | Maintains | Outperform → Outperform | — | $7.39 | $7.36 | -0.4% | -2.8% | +1.0% | +1.1% | +0.0% | -1.0% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.25 | $4.33 | +1.9% | +3.1% | -2.3% | +14.5% | -6.1% | +5.4% |
| Oct 16 | BTIG | Maintains | Buy → Buy | — | $1.94 | $2.06 | +6.2% | +0.5% | -1.0% | +20.2% | -2.6% | -8.8% |
| Sep 30 | BTIG | Maintains | Buy → Buy | — | $1.99 | $1.99 | +0.0% | +1.0% | -2.0% | +3.6% | -2.9% | -8.6% |
| Sep 22 | BTIG | Maintains | Buy → Buy | — | $2.31 | $2.42 | +4.8% | +0.4% | -3.0% | -2.7% | -4.1% | +1.4% |
No insider trades available.
8-K
Climb Bio, Inc. -- 8-K Filing
Jun 11
8-K
Climb Bio, Inc. -- 8-K Filing
Jun 5
8-K · 2.02
!! High
Climb Bio, Inc. -- 8-K 2.02: Earnings Results
Climb Bio reported earnings results via press release, though specific financial metrics aren't detailed in this filing summary, so investors should review the attached exhibit for performance details and guidance.
May 7
8-K · 7.01
! Medium
Climb Bio, Inc. -- 8-K 7.01: Regulation FD Disclosure
Climb Bio disclosed investor event materials via webcast, indicating the company is providing strategic updates to shareholders through formal disclosure channels.
May 5
8-K · 1.01
! Medium
Climb Bio, Inc. -- 8-K 1.01: Equity Issuance
Climb Bio raised $110 million through an equity issuance, strengthening its balance sheet for clinical development and operations.
Apr 28
8-K
Unknown — 8-K Filing
Tiffany Altschuller's appointment as Head of Investor Relations brings relevant biotech finance and IR experience to CLYM, potentially improving capital markets communication and shareholder engagement.
Apr 3
8-K
Climb Bio, Inc. -- 8-K Filing
Climb Bio (CLYM) advanced its immune-disease therapeutic pipeline throughout 2025 while maintaining disciplined execution, indicating progress toward clinical development goals for investors.
Mar 5
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Ultra-Small Company Market Fund | 73,800 | $506K | Mar 2026 |
| 2 | Ultra-Small Company Fund | 50,000 | $342K | Mar 2026 |
| 3 | Small Cap Core Fund | 10,016 | $69K | Mar 2026 |
| 4 | Guggenheim Active Allocation Fund | 41 | $293 | Feb 2026 |
Valuation
Market Cap
$776.4M
Enterprise Value
$675.4M
P/E (TTM)
-13.01x
Forward P/E
—
PEG Ratio
0.11x
P/B
4.84x
P/S
—
P/FCF
-14.24x
EV/EBITDA
—
Shares Out
67.8M
Financials (TTM)
Revenue
$0
Net Income
-$59.9M
EBITDA
-$67.8M
Free Cash Flow
-$54.5M
Op Cash Flow
-$54.4M
EPS Basic
$-0.88
EPS Diluted
$-0.88
EPS Forward
$-1.12
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$167.7M
Total Liab.
$7.3M
Total Equity
$160.5M
Cash
$101.1M
LT Debt
$0
Book Value/Sh
$2.37
Debt/Equity
0.00x
Current Ratio
15.16
Quick Ratio
15.16
Returns & Growth
ROE
-37.3%
ROA
-35.7%
ROIC
-42.2%
Rev Growth YoY
+0.0%
EPS Growth YoY
+42.5%
Price Returns
2W
-3.3%
1M
+23.4%
3M
+53.3%
6M
+479.9%
12M
+828.8%
Technicals
52W High
$12.22
52W Low
$1.18
50d MA
$10.33
200d MA
$5.51
RSI (14)
54.00
ATR (14)
$1.04
Beta
-0.20
Avg Volume
1.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$17.75
High
$25.00
Low
$11.00
Median
$17.50
Data updated apr 25, 2026 1:52am
· Source: financialmodelingprep.com